Please provide your email address to receive an email when new articles are posted on . There was a significant independent link between angiotensin-converting enzyme inhibitor use and all-cause ...
First-line durvalumab with arterial chemotherapy in major portal invaded hepatocellular carcinoma: The phase 2 DurHope study with biomolecular analyses. Comparative diagnostic accuracy and tumor ...
The prognostic impact of KRAS mutation in colorectal cancer patients: A meta-analysis of phase III clinical trials. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract ...
The phase 2 ASSIST trial showed that atrasentan has an additional antiproteinuric effect -- approximately 25% -- over 12 weeks in patients with earlier-stage IgA nephropathy already receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results